Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Compugen Announces Addition of Prof. Drew Pardoll to its SAB

Published: Wednesday, January 22, 2014
Last Updated: Wednesday, January 22, 2014
Bookmark and Share
Prof. Pardoll is a world leader in immuno-oncology research and in the development of novel cancer therapeutics.

Compugen Ltd. has announced that Drew Pardoll, MD, PhD, Abeloff Professor of Oncology, Medicine, Pathology, and Molecular Biology and Genetics at Johns Hopkins University of Medicine, has joined Compugen’s Scientific Advisory Board (SAB).

The SAB, disclosed in August 2013, provides insight and guidance on the Company’s activities in the fields of oncology and immunology with particular emphasis on its early stage pipeline of therapeutic proteins and monoclonal antibodies, largely based on Compugen-discovered immune checkpoint protein candidates.

Prof. Pardoll joins Compugen’s SAB, which already consists of Charles G. Drake, MD, PhD, Associate Professor of Oncology, Immunology and Urology at Johns Hopkins Kimmel Cancer Center; Iain B. McInnes, MD, PhD, Director of the Institute of Infection, Immunity, and Inflammation at the University of Glasgow; Antoni Ribas, MD, PhD, Professor at the Department of Medicine, Hematology/Oncology, University of California Los Angeles; and Howard R. Soule, PhD, Executive Vice President and Chief Science Officer, Prostate Cancer Foundation.

Anat Cohen-Dayag, PhD, President and CEO of Compugen, stated, “We are delighted to welcome Prof. Pardoll, a renowned scientist and key opinion leader in the field of immuno-oncology, to our SAB. We recently announced an increase of more than sixty percent in our R&D budget for the current year relative to 2013, primarily in support of our Pipeline Program candidates in immuno-oncology, and therefore very much look forward to benefiting from the knowledge and guidance to be provided by Drew and the other SAB members."

For the past two decades, Prof. Pardoll has studied molecular aspects of immune regulation, particularly related to mechanisms by which cancer cells evade elimination by the immune system.

Prof. Pardoll made seminal advances in immunology, including the discovery of new types of immune cells and regulatory mechanisms. He was the first to propose blockade of PD-1 for cancer therapy, and his program led the clinical development of the first anti-PD-1 antibody.

Prof. Pardoll is the inventor of a number of immunotherapies, including cancer vaccines, and was a scientific founder of Amplimmune Inc. He has served on the editorial boards of the Journal of the National Cancer Institute and Cancer Cell, and has been a member of numerous corporate and other scientific advisory boards.

Prof. Pardoll is Director of the Cancer Immunology Program in the Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins and completed his MD, PhD, Medical Residency and Oncology Fellowship at Johns Hopkins University.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Compugen Reports Fourth Quarter and Calendar 2013 Results
Company discloses key 2014 corporate objectives.
Wednesday, February 12, 2014
Compugen Establishes SAB to Guide Pipeline Program Development
Key opinion leaders to advise Company on research and development involving therapeutic product candidates in the fields of immunology and oncology.
Tuesday, August 27, 2013
Compugen Announces $15 Million Funding Agreement for its Keddem Subsidiary
Keddem's unique technology platform focuses on small molecule drug discovery.
Thursday, March 21, 2013
Compugen Announces Initial Validation Results for Two Novel Immunomodulatory Proteins
CGEN-15031 and CGEN-15051 demonstrate therapeutic potential in animal models of autoimmune diseases.
Tuesday, July 24, 2012
Compugen Reports First Quarter 2012 Financial Results
Non-cash Baize arrangements charges added significantly to loss for quarter.
Monday, May 07, 2012
Compugen Reports Fourth Quarter and Calendar 2011 Financial Results Feb 07, 2012
Immunomodulatory therapeutics program being extended beyond B7/CD28 family.
Thursday, February 09, 2012
Compugen Cancer Target Results Demonstrate Significant Potential for Cancer Immunotherapy
Findings support CGEN-15001T's potential as a powerful drug target for cancer immunotherapy.
Monday, February 06, 2012
Compugen to Broaden and Accelerate mAb Program for Oncology and Immunology
$8 million towards expanded program will be provided by Baize Investments via second research funding agreement with Compugen.
Thursday, December 22, 2011
Scientific News
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Long-Term Culturing of Adult Stem Cells
A new procedure developed by Harvard Stem Cell Institute researchers (HSCI) at Massachusetts General Hospital (MGH) may revolutionize the culturing of adult stem cells.
Solutions for Biotherapeutic Characterization
Innovation to speed the routine.
Plant-Based Vaccine Among Front Runners In Search For New Polio Jab
A researcher from Norwich is part of a consortium that has been awarded $1.5 million to develop safer polio vaccines, using a new technique developed at the John Innes Centre.
Harnessing Helpful Microbes
Seeking to further harness microbes’ many uses, the federal government has launched the National Microbiome Initiative (NMI) to “foster the integrated study of microbiomes across different ecosystems.”
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
Better Animal Model to Improve HIV Vaccine Development
Penn study identifies a new tool to produce better HIV vaccine designs.
First Large-Scale Proteogenomic Study of Breast Cancer
The study offers understanding of potential therapeutic targets.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!